Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT03382418, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 11 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE1
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .